June 03, 2020

Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis, a Rare and Severe Form of Kidney Disease

February 06, 2020

Complexa Names Elisabeth Leiderman, MD, MBA, Chief Business Officer

February 20, 2019

First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension ​

August 18, 2019

Complexa Names Theodore Danoff, MD, PhD, Chief Medical Officer

September 24, 2018

Complexa Presents Data Evaluating the Pharmacological Action of CXA-10 on Drug-metabolizing Transport Proteins at 2018 American College of Clinical Pharmacology Annual Meeting

July 25, 2018

Complexa Names William Leong, Vice President of Chemistry, Manufacturing and Controls

June 27, 2018

Complexa Announces Presentation of Phase 1 Data Evaluating Lead Candidate CXA-10 as a Disease-Modifying Therapy in Pulmonary Arterial Hypertension at PHA’s 2018 International PH Conference

June 01, 2018

First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat a Rare and Severe Form of Kidney Disease, Focal Segmental Glomerulosclerosis

May 14, 2018

Complexa Appoints Francisco D. Salva Chief Executive Officer and President

July 26, 2017

Complexa Raises $62 Million in Series C Financing to Test CXA-10 in Two Orphan Disease Proof-of- Concept Trials

November 12, 2015

Complexa Announces Successful Completion of Four Phase 1 Studies of CXA-10 and Planned Phase 2 Initiation in Multiple Orphan Indications during 2016

June 04, 2014

Complexa, Inc. Completes $13 Million Series B Financing to Further Advance Clinical Development of CXA-10

Please reload